Systemic Lupus Erythematosus Treatment Global Market Report 2023

“Systemic Lupus Erythematosus Treatment Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on systemic lupus erythematosus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for systemic lupus erythematosus treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The systemic lupus erythematosus treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug: Antimalarial Drugs; Non-Steroidal Anti-Inflammatory Drugs (NSAIDS); Corticosteroids; Immunosuppressive Drugs

• 2) By Route Of Administration: Sub-Cutaneous; Oral; Intravenous

• 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Sales

• Companies Mentioned: GlaxoSmithKline PLC; Aurinia Pharmaceuticals; Pfizer; Merck & Co; Anthera Pharmaceuticals

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the systemic lupus erythematosus treatment market are GlaxoSmithKline PLC, Aurinia Pharmaceuticals, Pfizer, Merck & Co, Anthera Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Inc., F. Hoffmann-La Roche Ltd., ImmuPharma PLC, Sanofi, Eli Lilly, Amgen, Inc., Johnson & Johnson Services, Inc., Lycera Corporation and Mylan NV.

The global systemic lupus erythematosus treatment market is expected to grow from $2.50 billion in 2023 to $2.74 billion in 2023 at a compound annual growth rate (CAGR) of 9.54%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The systemic lupus erythematosus treatment market is expected to reach $3.98 billion in 2027 at a CAGR of 9.84%.

The systemic lupus erythematosus treatment market consists of sales of systemic lupus erythematosus drugs including antimalarial drugs such as chlorquine, and hydrochlorquine, cytotoxic, and immunosuppressive drugs such as cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, biologics such as b-cell modulators, t-cell modulators, pro-inflammatory, as well as cytokine inhibitors, corticosteroids such as prednisone, hydrocortisone, dexamethasone, and other drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its own tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. It is the most common type of lupus and cannot be cured, but medical interventions and lifestyle changes can help control it. Treatment for systemic lupus erythematosus consists mostly of immunosuppressive drugs that inhibit the immune system's activity.

North America was the largest region in the systemic lupus erythematosus treatment market in 2022. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The major types of drugs in systemic lupus erythematosus treatment are antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, and immunosuppressive drugs. An antimalarial is a drug that prevents or treats malaria. Lupus symptoms can be effectively treated with anti-malaria drugs such as hydroxychloroquine (Plaquenil), chloroquine (Aralen), and quinacrine (Atabrine). By route of administration, it is segmented into subcutaneous, oral, and intravenous. Systemic lupus erythematosus treatment is used in several applications, such as hospital pharmacies, retail pharmacies, and online sales.

The rising number of autoimmune disorders is expected to propel the growth of the systemic lupus erythematosus treatment market going forward. An autoimmune disease refers to a condition in which a patient's immune system attacks his or her body. An autoimmune disease occurs when the immune system mistakes parts of the body as foreign. The body releases proteins called autoantibodies that attack healthy cells. Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. For instance, in June 2020, according to a report shared by the American Autoimmune Related Diseases Association (AARDA), a US-based nonprofit organization dedicated to autoimmune awareness, it was estimated that as many as 50 million Americans lived with an autoimmune disease, which cost $86 billion a year. Furthermore, in October 2021, according to an article shared by the City, University of London, a UK-based public research university, 4 million people in the UK, or 7% of the population, are estimated to have at least one autoimmune disease. Over 80 autoimmune disorders have been found, and their prevalence is increasing annually by 3-9%. Thus, the rising number of autoimmune disorders is driving the growth of the systemic lupus erythematosus treatment market.

The introduction of improved biologic agents is a key trend gaining popularity in the systemic lupus erythematosus treatment market. A biologic agent refers to a substance that is made from a living organism or its products and is used for the prevention, diagnosis, or treatment of cancer and other diseases. Major companies operating in the market are advancing toward the development of biologic agents that would be used to treat systemic lupus erythematosus in various age groups. For instance, in December 2020, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced the approval of BENLYSTA (belimumab) by the US Food and Drug Administration (FDA) for treating adult patients with active lupus nephritis (LN). Systemic lupus erythematosus (SLE) causes lupus nephritis, an inflammation of the kidneys. Benlysta is used for treating both SLE and LN. This approval also includes SLE and LN with both intravenous and subcutaneous formulations.

In March 2021, Merck, a US-based pharmaceutical company, acquired Pandion Therapeutics for $1.85 billion. Through this acquisition, Merck gained the TALON technology from Pandion Therapeutics, which would address unmet needs in autoimmune conditions by rebalancing the immune response. Pandion Therapeutics is a US-based biotechnology company focusing on developing novel therapeutics. The company's lead candidate, PT101, is an engineered IL-2 mutein combined with a protein backbone. PT101 treats autoimmune diseases, such as ulcerative colitis and systemic lupus erythematosus, by activating and expanding Tregs.

The countries covered in the systemic lupus erythematosus treatment market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The sytemic lupus erythematosus treatment market research report is one of a series of new reports from The Business Research Company that provides sytemic lupus erythematosus treatment market statistics, including sytemic lupus erythematosus treatment industry global market size, regional shares, competitors with a sytemic lupus erythematosus treatment market share, detailed sytemic lupus erythematosus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sytemic lupus erythematosus treatment industry. This sytemic lupus erythematosus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.